Routine MenACWY Immunisation Schedule for Children in Europe
In Europe, routine MenACWY vaccination for healthy children is NOT universally recommended across all age groups—most European countries primarily target adolescents (around age 11-12 years) with a single dose, while infant/toddler vaccination is generally reserved for high-risk groups only. 1
Key Differences from US Recommendations
The evidence provided is predominantly from US guidelines (ACIP/CDC and Pediatrics), which differ substantially from European practice. European countries have adopted more varied approaches based on local epidemiology 2.
European Vaccination Patterns
Healthy Children (Standard Risk)
Adolescent vaccination (age 11-12 years):
- Single dose of MenACWY conjugate vaccine is the predominant European approach
- This targets the secondary peak of disease incidence in adolescence
- Provides both direct protection and herd immunity through reduced carriage 3
Infants and young children (2 months to 10 years):
- Routine vaccination is NOT recommended for healthy children in this age group in most European countries 1
- Exception: Malta has introduced infant MenACWY vaccination 2
High-Risk Children Only
For children with specific risk factors, vaccination schedules vary by age:
Ages 2-6 months (high-risk only):
- MenACWY-CRM: 4 doses at 2,4,6, and 12 months 1
Ages 7-23 months (high-risk only):
- 2-dose series with second dose in the second year of life 1
Ages 2-10 years (high-risk only):
High-risk categories include:
- Persistent complement deficiencies (C3, C5-9, properdin, factor D, factor H)
- Functional or anatomic asplenia
- Travel to hyperendemic/epidemic areas (e.g., African "meningitis belt")
- Community outbreak situations 1
Booster Doses (High-Risk Only)
- If primary series before age 7 years: First booster at 3 years, then every 5 years 1
- If primary series at age ≥7 years: Booster every 5 years 1
Available Vaccines in Europe
- MenACWY-TT (Nimenrix™): Approved from 12 months of age 5, 6, 7
- MenACWY-CRM (Menveo): Standard from age 2 years 7
- MenACWY-D (Menactra): Available but with specific timing considerations relative to pneumococcal vaccines 1, 4
Critical Caveats
Important timing consideration: Children with asplenia should NOT receive MenACWY-D before age 2 years to avoid interference with pneumococcal conjugate vaccine (PCV) immune response. If used, administer at least 4 weeks after completing all PCV doses 4, 1.
Catch-up campaigns: European experience demonstrates that including adolescents in catch-up campaigns is crucial for achieving herd immunity, as this age group has high carriage rates 3.
Country-specific variations: Individual European countries have adopted different strategies based on local epidemiology, with some implementing infant programs and others focusing solely on adolescents 2. Check your specific country's national immunization program for exact recommendations.